10 Questions With Marketocracy Medical Specialists’ Ken Kam
|
|
Biotech stocks have been all the rage this year, but what exactly are they and where are they going from here? TheStreet.com sat down with Ken Kam, manager of the Marketocracy Medical Specialists fund, which invests primarily in stocks of biotech companies — high-tech shops that develop new medications and medical devices. Much of the interest in the sector is the result of the Human Genome Project, a joint public-private effort to map the human gene and help researchers get to the root of disease. Like biotech stocks, Kam’s fund has been a mercurial performer. But he’s got a different perspective because he spent years working in the biotech industry. He and Kevin Landis pioneered the concept of funds run by veterans of the industry in which they invest. He’s also adding some innovation to the fund business with his new Marketocracy Web site and fund shop. The idea: Amateur investors will run a virtual portfolio for three years, and those who perform best will then team up and run a real fund. More : thestreet.com |